DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the European Respiratory Society (ERS) Annual Congress September 18 - 22, 2010 in Barcelona, Spain. The data from Inspire’s first Phase 3 trial with denufosol (TIGER-1) suggest that denufosol, a novel inhaled ion channel regulator, has the potential to provide benefit in lung function for those patients on minimal pharmacotherapy.